BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Acadra acadesine: Phase I/IIa data

An open-label, dose-escalation, European Phase I/IIa trial in 24 patients with relapsed or refractory CLL showed that Acadra was well tolerated and led to reductions in leukemic tumor...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >